{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:52:58Z","timestamp":1765263178111,"version":"3.46.0"},"reference-count":36,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2025,11,2]]},"DOI":"10.1080\/13543784.2025.2598458","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T14:58:26Z","timestamp":1764428306000},"page":"819-824","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a)"],"prefix":"10.1080","volume":"34","author":[{"given":"Xuan L.","family":"Tang","sequence":"first","affiliation":[{"name":"Royal Perth Hospital & Fiona Stanley Hospital Network","place":["Perth, Western Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2171-1288","authenticated-orcid":false,"given":"Amanda J.","family":"Hooper","sequence":"additional","affiliation":[{"name":"Royal Perth Hospital & Fiona Stanley Hospital Network","place":["Perth, Western Australia"]},{"name":"University of Western Australia","place":["Perth, Western Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-6119","authenticated-orcid":false,"given":"John R.","family":"Burnett","sequence":"additional","affiliation":[{"name":"Royal Perth Hospital & Fiona Stanley Hospital Network","place":["Perth, Western Australia"]},{"name":"University of Western Australia","place":["Perth, Western Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000147"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024611"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000753"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050753"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.1470"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.801"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab171"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36204-7"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101549"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.08.007"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa649"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2851"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio1250"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R056549"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-019-0787-5"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61252-1"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2025.03.019"},{"key":"e_1_3_4_22_1","unstructured":"Ionis statement on Novartis\u2019 updated timing for phase 3 pelacarsen data readout. [cited 2025 Jun]. Available from: https:\/\/ir.ionis.com\/static-files\/66c5e90a-3651-480d-a596-1cf0d1a52991"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01634-w"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211023"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.05.058"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.21835"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415818"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.16503"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24017"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00721-4"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415820"},{"key":"e_1_3_4_32_1","unstructured":"Obicetrapib demonstrates significant reductions of Lp(a) on top of high-intensity statins. [cited 2025 Oct]. Available from: https:\/\/www.cardiometabolichealth.org\/wp-content\/uploads\/2024\/10\/7_2024-CMHC_Poster-07_NAP_Lpa.pdf"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.21957"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.03.029"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5050"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4504"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0736"},{"key":"e_1_3_4_38_1","unstructured":"Silence Therapeutics reports full year 2024 financial results and provides business update. 2025. Available from: https:\/\/silence-therapeutics.com\/investors\/press-releases\/press-releases-details\/2025\/Silence-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update\/"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2025.2598458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:48:17Z","timestamp":1765262897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2025.2598458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,2]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,2]]}},"alternative-id":["10.1080\/13543784.2025.2598458"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2025.2598458","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"type":"print","value":"1354-3784"},{"type":"electronic","value":"1744-7658"}],"subject":[],"published":{"date-parts":[[2025,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}